# Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

> **NCT01477489** · PHASE1 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 33 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Veliparib
- **RADIATION:** Standard radiation treatment

## Key facts

- **NCT ID:** NCT01477489
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2014-10
- **Final completion:** 2017-10
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01477489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01477489, "Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01477489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*